To investigate the value of multislice spiral computed tomography (MSCT) haemodynamic parameters in evaluating the efficacy of chemotherapy in patients with advanced gastric cancer.

120 patients with advanced gastric cancer admitted to our hospital between October 2021 and October 2023 who met the criteria for natriuresis were selected as study subjects. Fluorouracil-based combined with platinum-based chemotherapy was used, once every 3 weeks, for a total of 8 cycles. After patients completed 8 cycles of chemotherapy, they were divided into effective group (54 cases) and ineffective group (66 cases) according to the solid tumour efficacy evaluation criteria. Scanning was performed using MSCT to compare the changes in haemodynamic parameters before and after chemotherapy, including blood flow (BF), blood volume (BV), permeability surface (PS), perfusion blood flow (PBV), etc.

When efficacy was assessed after completion of the first and eighth cycles of chemotherapy, the overall effectiveness of the 120 patients with advanced gastric cancer was 32.50% (39/120) and 45.00% (54/120), respectively. After 8 cycles of chemotherapy, 120 patients with advanced gastric cancer showed a significant decreasing trend in the haemodynamic parameters BF, BV, PS and PBV by MSCT scanning, the difference was statistically significant (P<0.001). Before chemotherapy, the BF, PS and PBV of the effective group were higher than those of the ineffective group, and the BV was lower than those of the ineffective group. Although there were numerical differences between the two groups in the parameters of BF, BV, PS and PBV, none of them was statistically significant (P>0.05). Meanwhile, the decrease of these parameters in the effective group was more significant than that in the ineffective group (P<0.001). Compared with the ineffective group, patients in the effective group showed a more significant decrease in BF, BV, PS and PBV values (P<0.001).

MSCT haemodynamic parameters as important indicators of tumour angiogenesis and microcirculatory status, which can comprehensively assess the effect of chemotherapy in patients with advanced gastric cancer.